Alnylam Pharmaceuticals
ALNY
#641
Rank
NZ$55.99 B
Marketcap
$432.56
Share price
-1.30%
Change (1 day)
76.03%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -NZ$0.41 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$2.24 Billion. , an increase over its 2023 earnings that were of -NZ$0.56 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -NZ$0.42 Billion-24.59%
2023 -NZ$0.56 Billion-67.84%
2022 -NZ$1.73 Billion36.93%
2021 -NZ$1.26 Billion-8.04%
2020 -NZ$1.37 Billion-15.66%
2019 -NZ$1.63 Billion12.23%
2018 -NZ$1.45 Billion62.91%
2017 -NZ$0.89 Billion17.78%
2016 -NZ$0.76 Billion43.44%
2015 -NZ$0.53 Billion60.69%
2014 -NZ$0.33 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$97.37 Million27.48%
2010 -NZ$76.38 Million-10.92%
2009 -NZ$85.75 Million95.77%
2008 -NZ$43.8 Million
2006 -NZ$70.17 Million-9.13%
2005 -NZ$77.22 Million34.74%
2004 -NZ$57.31 Million36.79%
2003 -NZ$41.9 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$1.07 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.49 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.22 B-154.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$0.21 Billion-49.96%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$73.48 Million-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$24.22 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$14.10 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-NZ$0.51 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel